DarioHealth Corp. (DRIO) News

DarioHealth Corp. (DRIO): $5.93

-0.21 (-3.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter DRIO News Items

DRIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DRIO News Highlights

  • DRIO's 30 day story count now stands at 3.
  • Over the past 1 day, the trend for DRIO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest DRIO News From Around the Web

Below are the latest news stories about DarioHealth Corp that investors may wish to consider to help them evaluate DRIO as an investment opportunity.

LifeSci Capital Thinks DarioHealth’s Stock is Going to Recover

In a report released yesterday, Rakhit Rahul from LifeSci Capital maintained a Buy rating on DarioHealth (DRIO – Research Report), with a price target of $31.00. The company's shares closed last Tuesday at $8.80, close to its 52-week low of $7.56. According to TipRanks.com, Rahul has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.5% and a 0.0% success rate. Rahul covers the Healthcare sector, focusing on stocks such as Mountain Crest Acquisition II, Nano-X Imaging, and Lucira Health. Currently, the analyst consensus on DarioHealth is a Moderate Buy with an average price target of $22.50, a 164.1% upside from current levels.

Catie Powers on TipRanks | February 9, 2022

DarioHealth Publishes Clinical Outcomes Demonstrating the Impact of Using a Single Digital Therapeutics Platform for Multiple Conditions

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing blood pressure and diabetes together on the same digital platform in the leading peer-reviewed journal for digital medicine and health, the Journal of Medical Internet Research.

Yahoo | February 9, 2022

DarioHealth Announces Four New Employer Contracts

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new employers. The new accounts are expected to launch during the first and second quarters of 2022.

Yahoo | February 8, 2022

DRIO: 2022 Outlook, Physimax Acquisition

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Since Our Last Update Since our last update , DarioHealth Corp. (NASDAQ:DRIO) had issued a number of press releases. Five employer contracts, a contract with a provider, a benefits brokerage, and a large regional health plan were signed since mid-November. Dario hosted an Investor Webinar on January 19, 2022 highlighting

Yahoo | January 24, 2022

What You Need To Know About DarioHealth Corp.'s (NASDAQ:DRIO) Investor Composition

The big shareholder groups in DarioHealth Corp. ( NASDAQ:DRIO ) have power over the company. Large companies usually...

Yahoo | January 22, 2022

DarioHealth Enters Agreement to Acquire Physimax, a Leading Provider of Validated Computer Vision for Musculoskeletal Health

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market (the Company), announced it has entered into an agreement to purchase all of the right, title and interest in certain assets of Physimax Technologies Ltd. ("Physimax"), a leading provider of computer vision (CV) technology for Musculoskeletal (MSK) functional screening and predictive risk of injury assessment. Physimax's technology is currently in commercial use by NBA and NFL teams, the U.S. military and

Yahoo | January 20, 2022

DarioHealth Enters into Agreement with Large Regional Health Plan

DarioHealth Corp. (NASDAQ-CM: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has contracted with a large regional health plan (the "Plan") to deliver its digital therapeutic solution for diabetes for eligible Medicaid members in and around the mid-Atlantic region. The contract is expected to contribute to revenue beginning in the second quarter of 2022.

Yahoo | January 19, 2022

DarioHealth to Host Investor Webinar on Navigating Emerging Digital Health Trends for Strategic Growth in 2022

DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the emerging digital health trends in 2022 on Wednesday, January 19th at 8am ET.

Yahoo | January 18, 2022

DarioHealth Announces Two New Contracts within the Employer Market

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022.

Yahoo | January 6, 2022

DarioHealth (DRIO) Gets a Buy Rating from LifeSci Capital

E ratio of -2.80.

Brian Anderson on TipRanks | December 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6526 seconds.